Hundreds of new jobs to flow from Bristol-Myers Squibb Irish expansion



Hundreds of new jobs to flow from Bristol-Myers Squibb Irish expansion

NEW YORK - Bristol-Myers Squibb Company has announced plans to construct a new state-of-the-art, large-scale biologics manufacturing facility in Cruiserath, County Dublin.

The facility will produce multiple therapies for the company's growing biologics portfolio. When completed, it will significantly increase the company's biologics manufacturing capacity and play a central role in its global manufacturing network.

"Our investment in this new facility reflects the strength of our business and the increasingly important role that biologic medicines will play in Bristol-Myers Squibb's future," Lamberto Andreotti, Bristol-Myers Squibb CEO said Friday. "For 50 years, Bristol-Myers Squibb has maintained a significant manufacturing presence in Ireland, and we look forward to building on that legacy through this significant expansion of our manufacturing capability."

Enda Kenny, Taoiseach of Ireland said he welcomed the boost the construction of the facility will bring to his country's economy.

"I'm delighted they chose Ireland as the location for this large, state-of-the-art facility. Not only will 1,000 construction jobs be created in the initial phase, but the facility will support up to 400 jobs for skilled professionals," he said.

The 30,000-square meter project will house six 15,000-liter bioreactors and a purification area as well as office and laboratory space. The plant will be built on the grounds of the company's existing bulk pharmaceutical manufacturing plant.

Bristol-Myers Squibb's Board of Directors has approved initial funding that will support the first phase of the project. The full cost of the facility, expected to be finalized in the second half of 2015, is anticipated to be comparable to the approximately US $900 million investment to construct and operationalize the company's biologics manufacturing facility in Devens, Massachusetts.

Approximately 350 to 400 scientists, engineers, bioprocess operators, quality specialists and other skilled professionals are expected to work at the facility when construction is completed, and the construction program is expected to create about 1,000 jobs. The completion of the facility, including commissioning and validation, is anticipated to take approximately four years and is estimated to be operational in 2019.

Hundreds of new jobs to flow from Bristol-Myers Squibb Irish expansion

Hundreds of new jobs to flow from Bristol-Myers Squibb Irish expansion

Big News Network.com
14th November 2014, 23:13 GMT+11

NEW YORK - Bristol-Myers Squibb Company has announced plans to construct a new state-of-the-art, large-scale biologics manufacturing facility in Cruiserath, County Dublin.

The facility will produce multiple therapies for the company's growing biologics portfolio. When completed, it will significantly increase the company's biologics manufacturing capacity and play a central role in its global manufacturing network.

"Our investment in this new facility reflects the strength of our business and the increasingly important role that biologic medicines will play in Bristol-Myers Squibb's future," Lamberto Andreotti, Bristol-Myers Squibb CEO said Friday. "For 50 years, Bristol-Myers Squibb has maintained a significant manufacturing presence in Ireland, and we look forward to building on that legacy through this significant expansion of our manufacturing capability."

Enda Kenny, Taoiseach of Ireland said he welcomed the boost the construction of the facility will bring to his country's economy.

"I'm delighted they chose Ireland as the location for this large, state-of-the-art facility. Not only will 1,000 construction jobs be created in the initial phase, but the facility will support up to 400 jobs for skilled professionals," he said.

The 30,000-square meter project will house six 15,000-liter bioreactors and a purification area as well as office and laboratory space. The plant will be built on the grounds of the company's existing bulk pharmaceutical manufacturing plant.

Bristol-Myers Squibb's Board of Directors has approved initial funding that will support the first phase of the project. The full cost of the facility, expected to be finalized in the second half of 2015, is anticipated to be comparable to the approximately US $900 million investment to construct and operationalize the company's biologics manufacturing facility in Devens, Massachusetts.

Approximately 350 to 400 scientists, engineers, bioprocess operators, quality specialists and other skilled professionals are expected to work at the facility when construction is completed, and the construction program is expected to create about 1,000 jobs. The completion of the facility, including commissioning and validation, is anticipated to take approximately four years and is estimated to be operational in 2019.